Methods for detecting hepatocellular carcinoma
First Claim
Patent Images
1. A method of distinguishing hepatocellular carcinoma (HCC) from viral induced cirrhosis in a subject, comprising:
- a) measuring levels of at least three HCC markers selected from one or both of a first group (i) and a second group (ii) of markers in a biological sample from said subject to obtain a hepatocellular carcinoma marker profile from said subject;
b) comparing said marker profile to a control profile obtained from a viral-induced cirrhosis control sample, wherein differential expression of the at least three HCC markers in said biological sample compared to the control sample indicates a diagnosis of hepatocellular carcinoma in said subject; and
whereinc) said differential expression comprises decreased expression in said first group of HCC markers and increased expression in said second group of HCC markers, and whereind) said first group (i) consists of L-Selectin, IGFBP-6, IL-6sR, VCAM-1, FGF-basic, Fractalkine/CX3CL1, IL18; and
e) said second group (ii) consists of β
-Catenin, M-CSF, IL-8, MMP-10, Total p21, IL-1 ra, Resistin, interferon-gamma, BRAK/CXCL14, TNF-beta.
2 Assignments
0 Petitions
Accused Products
Abstract
A method for evaluating hepatocellular carcinoma in a subject is provided. In certain embodiments, the method comprises: a) obtaining a hepatocellular carcinoma protein marker profile for a sample obtained from the subject; and b) comparing the protein marker profile to a control profile.
-
Citations
15 Claims
-
1. A method of distinguishing hepatocellular carcinoma (HCC) from viral induced cirrhosis in a subject, comprising:
-
a) measuring levels of at least three HCC markers selected from one or both of a first group (i) and a second group (ii) of markers in a biological sample from said subject to obtain a hepatocellular carcinoma marker profile from said subject; b) comparing said marker profile to a control profile obtained from a viral-induced cirrhosis control sample, wherein differential expression of the at least three HCC markers in said biological sample compared to the control sample indicates a diagnosis of hepatocellular carcinoma in said subject; and
whereinc) said differential expression comprises decreased expression in said first group of HCC markers and increased expression in said second group of HCC markers, and wherein d) said first group (i) consists of L-Selectin, IGFBP-6, IL-6sR, VCAM-1, FGF-basic, Fractalkine/CX3CL1, IL18; and e) said second group (ii) consists of β
-Catenin, M-CSF, IL-8, MMP-10, Total p21, IL-1 ra, Resistin, interferon-gamma, BRAK/CXCL14, TNF-beta. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
2. A method of distinguishing hepatocellular carcinoma (HCC) from viral induced cirrhosis in a subject, comprising:
-
a) measuring levels of at least one HCC marker selected from the group consisting of M-CSF and MMP-10 in a biological sample from said subject to obtain a hepatocellular carcinoma marker profile from said subject; b) comparing said marker profile to a control profile obtained from a viral-induced cirrhosis control sample, wherein increased expression of the at least one HCC marker in said biological sample compared to the control profile indicates a diagnosis of hepatocellular carcinoma in said subject. - View Dependent Claims (15)
-
Specification